Tango, Erasca Begin Vopimetostat, ERAS-0015 Combination Trial

MT newswire2026/11/04 14:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:41 AM EST, 11/04/2026 (MT Newswires) -- Tango Therapeutics (TNGX) and Erasca (ERAS) said Wednesday their phase 1/2 study of vopimetostat in combination with ERAS-0015 in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant non-small cell lung cancer is now open for enrollment. The primary objective of the dose-escalation portion of the study is to determine the maximum tolerated dose, and the secondary objectives include antitumor activity, pharmacokinetics, safety and tolerability, the companies said. Price: 23.15, Change: -0.02, Percent Change: -0.09

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.

华尔街见闻•2026/11/10 00:42

Barrick’s Marquee gold project faces hazy study timing

Mining.com•2026/11/10 00:09